Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
Cardiff Oncology, Inc. (CRDF) will participate in the Cowen 44th Annual Health Care Conference with a fireside chat led by CEO Mark Erlander on March 4, 2024. The company aims to leverage PLK1 inhibition for novel cancer therapies.
02/26/2024 - 08:00 AM
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cowen 44th Annual Health Care Conference, which is taking place at the Marriott Copley Place in Boston from March 4-6, 2024.
Details of the fireside chat can be found below.
Presenter: Mark Erlander, CEODate: March 4, 2024Time: 1:30 pm – 2:00 PM ET
Interested parties can register for and access the live webcasts for these conferences by visiting the “Events ” section of the Cardiff Oncology website. The webcast replays will be available after the conclusion of the respective presentations.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact: jlevine@cardiffoncology.com
Investor Contact: Kiki@gilmartinir.com
Media Contact: richa@taftcommunications.com
When will Cardiff Oncology participate in the Cowen 44th Annual Health Care Conference?
Cardiff Oncology will participate in the Cowen 44th Annual Health Care Conference from March 4-6, 2024.
Who will be the presenter at the fireside chat for Cardiff Oncology at the conference?
Mark Erlander, the CEO of Cardiff Oncology, will be the presenter at the fireside chat.
Where can interested parties access the live webcasts for the conference?
Interested parties can access the live webcasts for the conference by visiting the 'Events' section of the Cardiff Oncology website.
Will there be webcast replays available after the presentations?
Yes, webcast replays will be available after the conclusion of the respective presentations.
CRDF Rankings
#4132 Ranked by Stock Gains
CRDF Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Services, Medical/Nursing Services, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
San Diego
About CRDF
trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary precision cancer monitoring® (pcm) technology in tumor genomics. trovagene has broad intellectual property and proprietary technology to measure circulating tumor dna (ctdna) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. trovagene offers its pcm technology at its clia/cap – accredited laboratory and plans to continue to vertically integrate its pcm technology with precision cancer therapeutics. trovagene's lead therapeutic asset is pcm-075, an oral, investigational drug and a highly-selective polo-like kinase 1 (plk1) inhibitor for the treatment of acute myeloid leukemia (aml). among the four members of the plk family, plk1 is recognized to be the fundamental component for cell division to take place correctly. most importantly, plk1 is only expressed in dividing cells, wh
